Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

ASP Isotopes Enters Final Stage for Helium Production

ASP Isotopes said its subsidiary Tetra4 has entered commissioning on the phase 1 liquid helium plant in South Africa, moving the Virginia gas project into the final startup stage for the helium portion of the facility.

Phase 1 is expected to produce about 2,500 gigajoules a day of LNG and about 70 thousand cubic feet a day of liquid helium. Commercial production is expected in the third quarter of 2026, with the company saying first commercial helium shipments are still targeted for September.

On a run-rate basis, the company said phase 1 could generate more than $27 million in annualized revenue, based on LNG pricing of $15 to $18 per gigajoule and helium at $600 per thousand cubic feet. ASP said it expects to begin recognizing those revenues in the second half of 2026.

The company said it has already signed take-or-pay contracts covering about 75% of phase 1 LNG output and 15% of phase 1 helium output. It expects to finish contracting for phase 1 during the third quarter of 2026.

ASP also said it expects to start phase 2 construction in the second half of 2026, describing that expansion as roughly 13 times the size of phase 1. The phase 2 build is expected to take about 44 months. The company said it is pursuing up to $750 million of senior debt funding for phase 2, with the U.S. International Development Finance Corporation and Standard Bank of South Africa previously indicating potential support of up to $500 million and $250 million, respectively.

ASP said it is also looking for ways to accelerate revenues and cash flow from phase 2. As a result of these announcements, the company's shares have moved -4.03% on the market, and are now trading at a price of $3.925. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS